GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily RelovairTM* in COPD and asthma
Jan 09, 2012